- Home
- HCC vs SWTX Comparison
HCC vs SWTX Comparison
Compare HCC & SWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCC
- SWTX
- Stock Information
- Founded
- HCC 2015
- SWTX 2017
- Country
- HCC United States
- SWTX United States
- Employees
- HCC N/A
- SWTX N/A
- Industry
- HCC Coal Mining
- SWTX Biotechnology: Pharmaceutical Preparations
- Sector
- HCC Energy
- SWTX Health Care
- Exchange
- HCC Nasdaq
- SWTX Nasdaq
- Market Cap
- HCC 2.5B
- SWTX 3.5B
- IPO Year
- HCC 2017
- SWTX 2019
- Fundamental
- Price
- HCC $45.30
- SWTX $46.20
- Analyst Decision
- HCC Strong Buy
- SWTX Buy
- Analyst Count
- HCC 5
- SWTX 7
- Target Price
- HCC $70.25
- SWTX $56.86
- AVG Volume (30 Days)
- HCC 869.0K
- SWTX 8.6M
- Earning Date
- HCC 04-30-2025
- SWTX 05-20-2025
- Dividend Yield
- HCC 0.71%
- SWTX N/A
- EPS Growth
- HCC N/A
- SWTX N/A
- EPS
- HCC 2.01
- SWTX N/A
- Revenue
- HCC $1,319,451,000.00
- SWTX $191,589,000.00
- Revenue This Year
- HCC N/A
- SWTX $86.36
- Revenue Next Year
- HCC $26.14
- SWTX $69.02
- P/E Ratio
- HCC $22.49
- SWTX N/A
- Revenue Growth
- HCC N/A
- SWTX 3417.33
- 52 Week Low
- HCC $38.00
- SWTX $28.21
- 52 Week High
- HCC $75.53
- SWTX $62.00
- Technical
- Relative Strength Index (RSI)
- HCC 42.76
- SWTX 58.72
- Support Level
- HCC $43.43
- SWTX $46.10
- Resistance Level
- HCC $47.79
- SWTX $46.27
- Average True Range (ATR)
- HCC 2.10
- SWTX 1.02
- MACD
- HCC -0.24
- SWTX 0.69
- Stochastic Oscillator
- HCC 26.45
- SWTX 98.93
About HCC Warrior Met Coal Inc.
Warrior Met Coal Inc is a U.S based company. It produces and exports of met coal that operates underground mines in Alabama. The company sells to steels manufacturers in Europe, Asia, and South America. Its mining operations consist of two underground met coal mines in Southern Appalachia's coal seam and other surface met and thermal coal mines. The Company generates ancillary revenues from the sale of natural gas extracted as a byproduct from the underground coal mines and royalty revenues from leased properties.
About SWTX SpringWorks Therapeutics Inc.
SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The company has a differentiated portfolio of small molecule targeted oncology product candidates and is advancing two potentially registrational clinical trials in rare tumor types, as well as several other programs addressing prevalent, genetically defined cancers. OGSIVEO, the first commercial product, is a novel, oral, selective gamma-secretase inhibitor. GOMEKLI, the second commercial product, is an oral, small molecule mitogen-activated protein kinase, or MEK, inhibitor.